A Prospective, Multi-Center Study of Phasix™ Mesh for Ventral or Incisional Hernia Repair.

Ventral Hernia Clinical Trial

Official title:

A Prospective, Multi-Center Study of Phasix™ Mesh for Ventral or Incisional Hernia Repair.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01961687
• Other study ID #: DVL-HE-011
• Status: Completed
• Phase: N/A
• Start date: September 2013
• Est. completion date: January 27, 2020

Study information

• Verified date: January 2021
• Source: C. R. Bard
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Single-arm study of Phasix Mesh in High Risk patients looking at SSI and recurrence rates.

Description:

The objective of this study is to collect additional data on safety, performance and effectiveness of Phasix™ Mesh in subjects requiring primary ventral, incisional or first-recurrent (protocol version 1.4)/multiply-recurrent (protocol version 2.0) hernia repair in subjects at high risk for complications. Subjects at high risk are defined as having 1 or more of the following co-morbidity conditions: body mass index (BMI) between 30-40 kg/m2, inclusive, active smokers, chronic obstructive pulmonary disease (COPD), diabetes, immunosuppression, coronary artery disease, chronic corticosteroid use, low pre-operative serum albumin, advanced age, or renal insufficiency.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 121
• Est. completion date: January 27, 2020
• Est. primary completion date: January 27, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subjects must have met all of the criteria listed below to be enrolled in the study:

1. Subject must have been 18 years of age or older 2. Subject or subject's legally authorized representative must have given written informed consent 3. Subject must have been diagnosed with primary ventral, incisional hernia or first time recurrent ventral or incisional hernia (protocol version 1.4) 3. Subject must be diagnosed with primary ventral, incisional hernia or multiply-recurrent (not to exceed 3 recurrences) ventral or incisional hernia (protocol version 2.0) 4. Subject must have had a hernia greater than 10 cm2 and =350 cm2 5. Subject must have been willing to undergo initial ventral, incisional or first recurrent incisional hernia repair using retro-rectus or onlay placement (using absorbable suture) with or without Component Separation Technique (CST) (protocol version 1.4) 5. Subject must be willing to undergo initial ventral, incisional or multiply-recurrent incisional hernia repair using retro-rectus or onlay placement (using absorbable suture) with or without Component Separation Technique (CST) (protocol version 2.0) 6. Subject met the criteria for a Class I wound as defined by the CDC (Appendix 4 of the protocol) 7. Subjects must have had 1 or more of the following pre-study conditions:

1. Body Mass Index (BMI) between 30-40 kg/m2, inclusive

2. Active smokers (if attempts to quit smoking within two weeks of surgery have failed and the patient was still an active smoker at the time of surgery)

3. COPD presence on patient self-report

4. Diabetes mellitus

5. Immunosuppression

6. Coronary Artery Disease

7. Chronic corticosteroid use: greater than 6 months systemic use

8. Serum albumin less than 3.4 g/dL

9. Advanced age: 75 years or older

10. Renal insufficiency, defined as serum creatinine concentration =2.5 mg/dL

Exclusion Criteria:

Subjects were excluded from study enrollment if any of the following criteria were met:

1. Subject's hernia had recurred more than once (protocol version 1.4)

1. Subject has had 4 or more previous hernia repairs (of the index hernia) (protocol version 2.0)

2. The subject had peritonitis

3. The subject was on or suspected to be placed on chemotherapy medications during any part of the study

4. The subject's Body Mass Index (BMI) was greater than 40 kg/m2

5. The subject had cirrhosis of the liver and/or ascites

6. Subject was American Society of Anesthesiology Class 4 or 5

7. Subject was known to be infected with human immunodeficiency virus (HIV)

8. Subject had a life expectancy of less than 2 years at the time of enrollment

9. Subject had any condition that, in the opinion of the Investigator, precluded the use of the study device, precluded the subject from completing the follow-up requirements

10. Subject's hernia repair utilized intraabdominal mesh placement

11. Subject had a surgical wound classified as Class II (Clean-Contaminated), Class III (Contaminated) or Class IV (Dirty-Contaminated) as defined by the CDC (Appendix 4 of the protocol)

12. Subject had an active or latent systemic infection

13. Subject required surgical bridge repair as the sole repair

14. Subject was pregnant or had plans to become pregnant during the study period or was breastfeeding

15. Subject had enrolled in another clinical study within the last 30 days

16. Subject was part of the site personnel directly involved with this study

17. Subject had a known allergy to the test device or component materials (patients with known allergies to tetracycline hydrochloride or kanamycin sulfate were avoided).

Related Conditions & MeSH terms

• Hernia
• Hernia, Ventral
• Incisional Hernia
• Ventral Hernia

Intervention

Device:
• Resorbable Mesh
Phasix Mesh

Locations

Country	Name	City	State
United States	Florida Hospital/Celebration Health	Celebration	Florida
United States	NorthShore University HealthSystem	Evanston	Illinois
United States	Univerity of Tennessee Health Science Center	Germantown	Tennessee
United States	Indiana University	Indianapolis	Indiana
United States	University of Tennessee Health Sciences Center	Knoxville	Tennessee
United States	University of Kentucky Medical Center	Lexington	Kentucky
United States	University of Wisconsin System	Madison	Wisconsin
United States	Medical College of Wisconsin	Milwaukee	Wisconsin
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Methodist Health System	Omaha	Nebraska
United States	Oregon Health and Science University	Portland	Oregon
United States	Virginia Commonwealth University	Richmond	Virginia
United States	University of California, San Diego	San Diego	California
United States	Baystate Medical Center	Springfield	Massachusetts
United States	Southeast Area Health and Education Center	Wilmington	North Carolina
United States	University of Massachusetts Worcester	Worcester	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
C. R. Bard	FGK Clinical Research GmbH

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hernia Recurrence Rate	Hernia recurrence rates will be assessed by physical examination at each study visit through 60 months. A recurrent hernia will be defined as any hernia identified or confirmed by the investigator, during any study follow-up visit, in approximately the same position as the hernia repaired in the study procedure. Potential hernias identified via incidental magnetic resonance imaging (MRI) or computed tomography (CT) scan will be evaluated by the operating surgeon for clinical significance and confirmation of hernia recurrence.	60 Months
Primary	Surgical Site Infections	Infections at the surgical site will be assessed by physical examination at each study visit through 60 months. If an infection is suspected, a routine culture, obtained via each site's standard protocol, should be obtained to determine cell count and type (i.e. yeast, gram positive or gram negative bacteria, or other). If genus and species of the culture are identified as part of the routine practice at the site, that information should be recorded. Classification will follow the CDC guidelines for superficial and deep surgical site infections	60 Months
Secondary	Pain Visual Analog Scale	Mean change in self-reported pain measured on a Visual Analog Scale between Baseline and 60-month follow up. Scores are measured on a scale from 0.0 to 10.0 centimeters and marked on a line by the subject; lower values correspond with low pain perception. The outcome measure is presented as the mean of the absolute difference between the pain perception at Baseline and the pain perception at 60-month follow up. A negative score means a decrease in pain perception.	60 Months
Secondary	Device Related Adverse Events	Incidence of device related adverse events: number of subjects with one or more possibly or definitely device related adverse events. The term "incidence" is an error and is reported here as the rate of device related adverse events.	60 Months
Secondary	Rate of Re-operation Due to the Index Hernia Repair	Rate of re-operation due to the index hernia repair; the proportion of subjects with post-procedure re-operation due do the index hernia repair.	60 Months
Secondary	Carolinas Comfort Scale® (CCS)	Each scale score (sensation of mesh, pain or movement limitations) ranges from 0-5 and is a summation of scores across the domains. Therefore, the Total CCS Score ranges from 0-115 and is the average of the 3 scale scores. Low scores represent fewer symptoms or difficulties.; Absolute values of the Total CCS Score at 1-Month follow-up, at 3-Month follow-up, at 6-Month follow-up, 12-Month follow-up, 18-Month follow up, at 24-Month follow-up, 36-Month follow-up, 48-Month follow-up, and 60-Month follow-up are reported.; The absolute value at Baseline, or a change in self-reported quality of life measured by Carolinas Comfort Scale® cannot be reported, as subjects had incorrectly answered the questions on Sensation of Mesh at Baseline where no Phasix Mesh was yet implanted, thereby creating a bias in the results.	60 Months
Secondary	SF-12 Questionnaire	The Short Form (SF)-12 version 2 (v2) is a multi-purpose, twelve item health survey that measures seven domains of health: general health, physical functioning, role limitations due to physical health (role-physical), role limitations due to emotional problems (role-emotional), bodily pain, vitality and mental health and social functioning. The SF-12v2 yields scale scores for each of these seven health domains, and two summary measures of physical and mental health: the physical component summary (PCS) and mental component summary (MCS). The scores range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.	60 Months
Secondary	Surgical Procedure Time as Measured From Incision to Closure	Surgical procedure time as measured from incision to closure (skin to skin)	1 day
Secondary	Length of Hospital Stay	Time in days from hospital admission to discharge	35 days